Treatment of Vestibular Migraine
For vestibular migraine, initiate preventive therapy with flunarizine 10 mg/day as first-line treatment based on the strongest available evidence, with propranolol, valproic acid, or venlafaxine as second-line alternatives; for acute attacks, use triptans only when headache is present, not for isolated vertigo episodes.
Acute/Abortive Management
When to Use Triptans
- Use triptans when vestibular migraine attacks include headache 1, 2
- Do NOT use triptans for isolated vertigo/dizziness episodes without headache 1
- Evidence-supported triptans include: sumatriptan (oral and subcutaneous), naratriptan, rizatriptan, and zolmitriptan 3
Symptomatic Treatment
- Treat nausea aggressively with antiemetics - nausea is one of the most disabling symptoms and should not be undertreated 3
- Consider non-oral routes when nausea/vomiting is prominent 3
- NSAIDs (aspirin, ibuprofen, naproxen sodium) can be tried for mild-to-moderate attacks with headache 3, 4
Important Caveat
Avoid opioids - they carry abuse risk, cause sedation, and can lead to medication-overuse headache 3, 5
Preventive Therapy
Indications for Prevention
Initiate preventive therapy when patients have 3:
- ≥2 attacks per month causing disability lasting ≥3 days/month
- Contraindication to or failure of acute treatments
- Use of abortive medication >2 times per week
- Significant quality of life impairment
First-Line: Flunarizine
Flunarizine 10 mg/day is the preferred first-line preventive agent 6, 2, 7
- Supported by two randomized controlled trials specifically for vestibular migraine
- Recent 2025 network meta-analysis and 2026 retrospective study (402 patients) confirm efficacy 6, 7
- 81-84% response rate (≥50% reduction in vertigo attacks) 7
- Reduces monthly vertigo attacks from ~1.6 to 0.2 per month over 8 months 7
Side effects to monitor:
- Sedation, weight gain, abdominal pain 3
- Depression and extrapyramidal symptoms (particularly in elderly) 3
- Generally mild and reversible 7
Note: Flunarizine is not available in all countries (including the United States)
Second-Line Options (When Flunarizine Unavailable or Failed)
Propranolol 80-240 mg/day 6, 2
- Ranked highest in 2025 network meta-analysis for reducing vertigo frequency (P-score: 0.794) 6
- Reduces attacks by ~7 per month 6
- Proven efficacy for general migraine prevention 3
Valproic acid/Divalproex sodium 500-1500 mg/day 6, 2
Venlafaxine (dose per clinical judgment) 6, 2
- Reduces vertigo attacks by ~6 per month 6
- Useful when comorbid depression or anxiety present
Topiramate 2
- Evidence from general migraine prevention 3
- Consider when obesity is comorbid (causes weight loss) 8
- Start low, titrate slowly due to cognitive side effects
Emerging Therapies
CGRP Antagonists (Galcanezumab, others) 1, 9, 6
- Moderate efficacy with excellent tolerability (zero discontinuations in trials) 6
- Reduces vertigo attacks by ~5.8 per month 6
- Best balance of efficacy, tolerability, and evidence quality among newer agents 6
- Still being researched; initial results promising but expensive 1, 9
Botulinum toxin A 1
- Under investigation for vestibular migraine
- Proven only for chronic migraine (≥15 headache days/month), not episodic migraine 5, 8
Non-Pharmacological Approaches
Vestibular Rehabilitation 2, 10
- Sound prophylactic treatment option
- Should be incorporated into comprehensive management
- Helps with cerebellar compensation mechanisms 9
Lifestyle Modifications 8
- Identify and modify risk factors for chronic transformation
- Address comorbidities: anxiety, depression, sleep disturbances, obesity 8
- Patient education about medication-overuse headache risk 3
Treatment Algorithm
Step 1: Confirm Diagnosis
- ≥5 vertigo attacks lasting 5 minutes to 72 hours
- Current or past history of migraine with/without aura
- ≥50% of attacks accompanied by migraine features (headache, photophobia, phonophobia, visual aura)
- Rule out benign paroxysmal positional vertigo, Menière's disease, stroke 1, 9
Step 2: Assess Need for Prevention
If ≥2 disabling attacks per month or frequent acute medication use → initiate prevention
Step 3: Choose Preventive Agent
- First choice: Flunarizine 10 mg/day (if available)
- If unavailable: Propranolol 80-240 mg/day OR valproic acid 500-1500 mg/day
- If depression/anxiety: Venlafaxine or amitriptyline 30-150 mg/day
- If obesity: Topiramate
- If multiple preventives failed: Consider CGRP antagonist (galcanezumab)
Step 4: Titration and Trial Period
- Start low, titrate slowly to minimize adverse effects 3
- Allow 2-3 months for full therapeutic effect 3
- Monitor with vertigo diary: frequency, severity, duration, disability 3
Step 5: Acute Treatment Plan
- If headache present: Triptan (sumatriptan, rizatriptan, zolmitriptan) 3
- If isolated vertigo: Antiemetic for nausea, avoid triptans 1
- Avoid: Opioids, frequent use of any acute medication (>2×/week) 3
Step 6: Reassess and Adjust
- After stability period, consider tapering or discontinuing preventive therapy 3
- Address comorbidities that may perpetuate symptoms 8
Critical Pitfalls to Avoid
- Using triptans for isolated vertigo without headache - ineffective and potentially harmful 1
- Medication overuse - can transform episodic to chronic symptoms 3, 8
- Inadequate trial duration - stopping preventive therapy before 2-3 months 3
- Ignoring comorbidities - depression, anxiety, sleep disorders worsen outcomes 8
- Prescribing opioids - leads to dependence and medication-overuse headache 3, 5
Evidence Quality Note
The evidence base for vestibular migraine treatment remains limited compared to general migraine 9, 10. Most recommendations extrapolate from migraine studies, with flunarizine being the notable exception having vestibular migraine-specific trials 6, 2, 7. The 2025 network meta-analysis provides the most comprehensive comparative data available, though certainty remains moderate at best 6.